Efficacy and tolerability of toremifene and tamoxifen therapy in premenopausal patients with operable breast cancer: A retrospective analysis

Current Oncology

Volumn 20, Issue 4, 2013, Pages 196-204

  Qin, T ^a   Yuan, Z Y ^a   Peng, R J ^a   Zeng, Y D ^b   Shi, Y X ^a   Teng, X Y ^a   Liu, D G ^a   Bai, B ^a   Wang, Shu Sen ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Adjuvant endocrine therapy; Breast cancer; Premenopausal; Tamoxifen; Toremifene

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN; TOREMIFENE;

ADULT; ARTICLE; BLURRED VISION; BREAST CANCER; CATARACT; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRY EYE; ENDOMETRIUM CANCER; FATIGUE; FATTY LIVER; FEMALE; FLUSHING; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSOMNIA; LIVER CYST; MAJOR CLINICAL STUDY; MASTECTOMY; MENSTRUAL IRREGULARITY; NAUSEA; OVARY CYST; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PREMENOPAUSE; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL RATE; SWEATING; THROMBOEMBOLISM; VAGINA DISCHARGE; WEIGHT GAIN;

EID: 84881259762     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.20.1231     Document Type: Article

References (19)

1. Goldstein LJ. Controversies in adjuvant endocrine treatment of premenopausal women. Clin Breast Cancer 2006;6(suppl 2):S36-40.
2. Bao T, Davidson NE. Adjuvant endocrine therapy for premenopausal women with early breast cancer. Breast Cancer Res 2007;9:115.
3. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ on behalf of the 10th St. Gallen conference. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007;18:1133-44.
4. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005;365:1687-717.
5. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609-18.
6. Lewis JD, Chagpar AB, Shaughnessy EA, Nurko J, McMasters K, Edwards MJ. Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer. Cancer 2010;116:2307-15.
7. Pagani O, Gelber S, Price K, et al. on behalf of the International Breast Cancer Study Group. Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann Oncol 2004;15:1749-59.
8. Pukkala E, Kyyrönen P, Sankila R, Holli K. Tamoxifen and toremifene treatment of breast cancer and risk of subsequent endometrial cancer: a population-based case-control study. Int J Cancer 2002;100:337-41.
9. Parkkari M, Paakkala AM, Salminen L, Holli K on behalf of the Finnish Breast Cancer Group. Ocular side-effects in breast cancer patients treated with tamoxifen and toremifene: a randomized follow-up study. Acta Opthalmol Scand 2003;81:495-9.
10. Pyrhonen S, Ellmen J, Vuorinen J, et al. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat 1999;56:133-43.
11. National Comprehensive Cancer Network (nccn). NCCN Guidelines for Patients: Breast Cancer. Ver. 2.2011. Fort Washington, PA: nccn; 2011. [Available online at: http://www.nccn.com/files/cancer-guidelines/breast/index.html; cited August 9, 2012]
12. United States, Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Cancer Therapy Evaluation Program (ctep). Common Terminology Criteria for Adverse Events. Ver. 3.0. Bethesda, MD: ctep; 2003.
13. Gu R, Jia W, Zeng Y, et al. A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study. BMC Cancer 2012;12:161.
14. Holli K, Valavaara R, Blanco G, et al. Safety and efficacy of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. J Clin Oncol 2000;18:3487-94.
15. Harvey HA, Kimura M, Hajba A. Toremifene: an evaluation of its safety profile. Breast 2006;15:142-57.
16. El Saghir NS, Seoud M, Khalil MK, et al. Effects of young age at presentation on survival in breast cancer. BMC Cancer 2006;6:194.
17. Han W, Kang SY on behalf of the Korean Breast Cancer Society. Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer. Breast Cancer Res Treat 2010;119:193-200.
18. De Laurentiis M, Arpino G, Massarelli E, et al. A metaanalysis on the interaction between her-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005;11:4741-8.
19. Kim MJ, Dalton JT, Veverka KA. Relationship of CYP2D6 status and toremifene metabolism [abstract e13068]. J Clin Oncol 2011;29:. [Available online at: http://meetinglibrary.asco.org/content/85124-102; cited May 26, 2013]